Forum Financial Management LP Invests $221,000 in DaVita Inc. (NYSE:DVA)

Forum Financial Management LP acquired a new stake in DaVita Inc. (NYSE:DVA) in the 3rd quarter, HoldingsChannel.com reports. The institutional investor acquired 1,348 shares of the company’s stock, valued at approximately $221,000.

Other large investors also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. raised its position in shares of DaVita by 1.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,759 shares of the company’s stock valued at $776,000 after acquiring an additional 70 shares in the last quarter. Wedmont Private Capital increased its stake in DaVita by 4.4% during the third quarter. Wedmont Private Capital now owns 1,776 shares of the company’s stock valued at $280,000 after purchasing an additional 75 shares during the last quarter. Blue Trust Inc. raised its holdings in shares of DaVita by 58.6% during the second quarter. Blue Trust Inc. now owns 211 shares of the company’s stock worth $29,000 after purchasing an additional 78 shares during the period. First Trust Direct Indexing L.P. lifted its position in shares of DaVita by 2.9% in the 3rd quarter. First Trust Direct Indexing L.P. now owns 3,051 shares of the company’s stock worth $500,000 after buying an additional 86 shares during the last quarter. Finally, Nisa Investment Advisors LLC boosted its holdings in shares of DaVita by 0.3% in the 3rd quarter. Nisa Investment Advisors LLC now owns 36,820 shares of the company’s stock valued at $6,036,000 after buying an additional 126 shares during the period. Institutional investors own 90.12% of the company’s stock.

Insider Buying and Selling

In other DaVita news, insider Kathleen Alyce Waters sold 7,857 shares of the stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the completion of the transaction, the insider now directly owns 83,011 shares of the company’s stock, valued at approximately $12,137,038.31. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, insider Kathleen Alyce Waters sold 7,857 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the completion of the transaction, the insider now owns 83,011 shares in the company, valued at approximately $12,137,038.31. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO Michael David Staffieri sold 9,539 shares of the business’s stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $150.03, for a total transaction of $1,431,136.17. Following the completion of the sale, the chief operating officer now owns 241,945 shares in the company, valued at $36,299,008.35. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 173,482 shares of company stock valued at $27,387,069 over the last quarter. Corporate insiders own 2.00% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on DVA shares. Barclays raised their target price on shares of DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Bank of America boosted their price objective on DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research report on Wednesday, August 7th. Truist Financial increased their target price on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research report on Monday, October 7th. TD Cowen boosted their price target on shares of DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a report on Wednesday, July 24th. Finally, UBS Group lifted their price objective on shares of DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, DaVita has a consensus rating of “Hold” and a consensus target price of $161.80.

DaVita Price Performance

Shares of NYSE DVA opened at $147.08 on Wednesday. The stock has a market cap of $12.06 billion, a P/E ratio of 15.87, a P/E/G ratio of 0.80 and a beta of 0.89. The firm’s 50-day simple moving average is $157.52 and its 200 day simple moving average is $146.43. DaVita Inc. has a fifty-two week low of $78.05 and a fifty-two week high of $168.50. The company has a quick ratio of 1.33, a current ratio of 1.37 and a debt-to-equity ratio of 15.78.

DaVita (NYSE:DVA) last released its earnings results on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing the consensus estimate of $2.76 by ($0.17). The company had revenue of $3.26 billion for the quarter, compared to analyst estimates of $3.25 billion. DaVita had a net margin of 6.53% and a return on equity of 88.18%. The firm’s quarterly revenue was up 4.6% on a year-over-year basis. During the same period in the previous year, the business posted $2.85 EPS. Equities analysts expect that DaVita Inc. will post 9.73 EPS for the current year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.